Skip to main content

Research Repository

Advanced Search

Outputs (19)

Meta-analyses of Phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer (2021)
Journal Article
Robertson, J. F., Paridaens, R. J., Lichfield, J., Bradbury, I., & Campbell, C. (2021). Meta-analyses of Phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer. European Journal of Cancer, 145, 19-28. https://doi.org/10.1016/j.ejca.2020.11.038

Background
Four randomised controlled trials (RCTs) in postmenopausal women with advanced breast cancer (ABC) comparing aromatase inhibitors (AIs) versus the selective estrogen receptor modulator tamoxifen, each individually reported significantly... Read More about Meta-analyses of Phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial (2020)
Journal Article
Smith, I., Robertson, J., Kilburn, L., Wilcox, M., Evans, A., Holcombe, C., Horgan, K., Kirwan, C., Mallon, E., Sibbering, M., Skene, A., Vidya, R., Cheang, M., Banerji, J., Morden, J., Sidhu, K., Dodson, A., Bliss, J. M., & Dowsett, M. (2020). Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncology, 21(11), 1443-1454. https://doi.org/10.1016/S1470-2045%2820%2930458-7

Background: Preoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It has also been suggested that tumour Ki67 values after 2 w... Read More about Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.

Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance (2020)
Journal Article
Campbell, C., Mathew, J., Ellis, I. O., Bradbury, I., Borgquist, S., Elebro, K., Green, A. R., Finlay, P., Gee, J. M. W., & Robertson, J. F. R. (2020). Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance. Translational Breast Cancer Research, 1, Article 29. https://doi.org/10.21037/tbcr-20-31

Background: It remains clinically important to identify ER positive breast cancers likely to respond to tamoxifen (TAM) and so we aimed to select a group of biomarkers able to predict response. We also assessed whether data from different sample type... Read More about Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance.

The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ (2020)
Journal Article
Miligy, I. M., Toss, M. S., Shiino, S., Oni, G., Syed, B. M., Khout, H., Tan, Q., Green, A. R., Macmillan, R. D., Robertson, J. F. R., & Rakha, E. A. (2020). The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. British Journal of Cancer, 123(10), 1513-1520. https://doi.org/10.1038/s41416-020-1023-3

Background: Oestrogen receptor (ER) in invasive breast cancer (BC) predicts response to endocrine therapy (ET) and provides prognostic value. In this study, we investigated the value of ER expression in ductal carcinoma in situ (DCIS) in terms of out... Read More about The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ.

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer (2020)
Journal Article
Robertson, J. F., Evans, A., Henschen, S., Kirwan, C. C., Jahan, A., Kenny, L. M., Dixon, J. M., Schmid, P., Kothari, A., Mohamed, O., Fasching, P. A., Cheung, K. L., Wuerstlein, R., Carroll, D., Klinowska, T., Lindemann, J. P., MacDonald, A., Mather, R., Maudsley, R., Moschetta, M., …Harbeck, N. (2020). A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer. Clinical Cancer Research, 26(16), 4242-4249. https://doi.org/10.1158/1078-0432.CCR-19-3387

©2020 American Association for Cancer Research. PURPOSE: Fulvestrant, the first-in-class selective estrogen receptor (ER) degrader (SERD), is clinically effective in patients with ER+ breast cancer, but it has administration and pharmacokinetic limit... Read More about A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer.

Unconditional and conditional monetary incentives to increase response to mailed questionnaires: A randomized controlled study within a trial (SWAT) (2019)
Journal Article
Young, B., Bedford, L., das Nair, R., Gallant, S., Littleford, R., Robertson, J. F., Schembri, S., Sullivan, F. M., Vedhara, K., Kendrick, D., & ECLS Study Team. (2020). Unconditional and conditional monetary incentives to increase response to mailed questionnaires: A randomized controlled study within a trial (SWAT). Journal of Evaluation in Clinical Practice, 26(3), 893-902. https://doi.org/10.1111/jep.13230

Rationale, aims, and objectives: High response rates to research questionnaires can help to ensure results are more representative of the population studied and provide increased statistical power, on which the study may have been predicated. Improvi... Read More about Unconditional and conditional monetary incentives to increase response to mailed questionnaires: A randomized controlled study within a trial (SWAT).

Determinants of motivation to quit in smokers screened for the early detection of lung cancer: a qualitative study (2018)
Journal Article
Young, B., Vedhara, K., Kendrick, D., Littleford, R., Robertson, J. F. R., Sullivan, F. M., Schembri, S., das Nair, R., & in collaboration with the ECLS study team. (2018). Determinants of motivation to quit in smokers screened for the early detection of lung cancer: a qualitative study. BMC Public Health, 18(1), Article 1276. https://doi.org/10.1186/s12889-018-6211-1

Background: The promotion of smoking cessation within lung cancer screening could lead to benefits for smoking-related disease and improve cost-effectiveness of screening. Little is known about how smokers respond to lung cancer screening and how thi... Read More about Determinants of motivation to quit in smokers screened for the early detection of lung cancer: a qualitative study.

Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer (2018)
Journal Article
Robertson, J. F., Cheung, K.-L., Noguchi, S., Shao, Z., Degboe, A., Lichfield, J., Thirlwell, J., Fazal, M., & Ellis, M. J. (2018). Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. European Journal of Cancer, 94, https://doi.org/10.1016/j.ejca.2018.02.026

Background
The phase III randomised FALCON trial (NCT01602380) demonstrated improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg in endocrine therapy-naïve postmenopausal women with hormone receptor-positive (HR+) local... Read More about Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.